Compositions and methods for modulating hemoglobin gene family expression
First Claim
Patent Images
1. A single stranded oligonucleotide produced by a process comprising:
- synthesizing a single stranded oligonucleotide that;
(a) has a sequence 5′
-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 4-9 nucleotides in length,(b) is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a human hemoglobin gene, wherein the PRC2-associated region is a region of the hemoglobin gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the hemoglobin gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody; and
(c) is 11 to 16 nucleotides in length, wherein, during the synthesis, at least one nucleotide incorporated into the oligonucleotide is a nucleotide analogue.
6 Assignments
0 Petitions
Accused Products
Abstract
Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes (HBB, HBD, HBE1, HBG1 or HBG2). Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes. Methods for modulating expression of hemoglobin genes using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of hemoglobin genes.
-
Citations
31 Claims
-
1. A single stranded oligonucleotide produced by a process comprising:
-
synthesizing a single stranded oligonucleotide that; (a) has a sequence 5′
-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 4-9 nucleotides in length,(b) is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a human hemoglobin gene, wherein the PRC2-associated region is a region of the hemoglobin gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the hemoglobin gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody; and (c) is 11 to 16 nucleotides in length, wherein, during the synthesis, at least one nucleotide incorporated into the oligonucleotide is a nucleotide analogue. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 25, 26, 27, 28, 29, 30, 31)
-
-
23. A single stranded oligonucleotide produced by a process comprising:
-
synthesizing a single stranded oligonucleotide that; (a) comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a human hemoglobin gene, wherein the PRC2-associated region is a region of the hemoglobin gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the hemoglobin gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody; (b) is between 11 and 16 nucleotides in length and has at least one of; i) a sequence that is 5′
X-Y-Z, wherein X is any nucleotide and wherein X is anchored at the 5′
end of the oligonucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of 4 to 9 nucleotides in length;ii) a sequence that does not comprise three or more consecutive guanosine nucleotides; iii) a sequence that is complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising at least two single stranded loops; and
/oriv) a sequence that has greater than 60% G-C content; wherein, during the synthesis, at least one nucleotide incorporated into the oligonucleotide is a nucleotide analogue. - View Dependent Claims (24)
-
Specification